We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+39.2%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$505M
Cap. Flow
+$114M
Cap. Flow %
7.17%
Top 10 Hldgs %
57.57%
Holding
93
New
29
Increased
21
Reduced
9
Closed
17

Top Buys

Rank Stock Value
1
AKUS
Akouos Inc
AKUS
+$33.8M
2
GILD icon
Gilead Sciences
GILD
+$30.9M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$26.9M
4
LLY icon
Eli Lilly
LLY
+$22.9M
5
ABBV icon
AbbVie
ABBV
+$17.8M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$27.6M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.4M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.6M
4
BIIB icon
Biogen
BIIB
+$16.6M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.94M

Sector Composition

Rank Sector Weight
1 Healthcare 91.07%
2 Miscellaneous 8.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
76
DELISTED
Akero Therapeutics
AKRO
– –
-148,415
Closed -$3.15M
AKRO
77
PUT
DELISTED
Akero Therapeutics
AKRO
– –
-150,000
Closed -$3.18M
ALGN icon
78
Align Technology
ALGN
$10.9B
– –
-46,500
Closed -$8.09M
BIIB icon
79
Biogen
BIIB
$31.1B
– –
-52,628
Closed -$16.6M
FATE icon
80
Fate Therapeutics
FATE
$292M
– –
-36,564
Closed -$812K
FOLD
81
DELISTED
Amicus Therapeutics
FOLD
– –
-525,530
Closed -$4.86M
GILD icon
82
CALL
Gilead Sciences
GILD
$181B
– –
-100,000
Closed -$7.48M
HRTX icon
83
Heron Therapeutics
HRTX
$63.2M
– –
-481,608
Closed -$5.65M
IOVA icon
84
CALL
Iovance Biotherapeutics
IOVA
$3.82B
– –
-150,000
Closed -$4.49M
ITRM
85
DELISTED
Iterum Therapeutics
ITRM
– –
-115,101
Closed -$4.68M
KALA icon
86
PUT
KALA BIO
KALA
$10.8M
– –
-295
Closed -$6.48M
SAGE
87
DELISTED
Sage Therapeutics
SAGE
– –
-74,430
Closed -$2.14M
SRPT icon
88
Sarepta Therapeutics
SRPT
$2.33B
– –
-101,603
Closed -$9.94M
VRTX icon
89
Vertex Pharmaceuticals
VRTX
$132B
– –
-85,664
Closed -$20.4M
ALXN
90
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-307,300
Closed -$27.6M
ZGNX
91
DELISTED
Zogenix, Inc.
ZGNX
– –
-32,983
Closed -$816K
1 2 3
4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q2 2020 Portfolio in Review

As of Q2 2020, Sofinnova Investments held 93 positions worth $1.59B, up 47% from $1.08B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Sofinnova Investments deployed $114M of net new capital in Q2 2020, opening 29 new positions and adding to 21 existing holdings. Its largest new stake was Akouos Inc: 1,515,073 shares worth $34.1M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 96% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $17.6M trimmed.

  • Sofinnova Investments's largest Q2 2020 buy was Akouos Inc: 1,515,073 shares worth $34.1M.
  • Sofinnova Investments added most to AbbVie in Q2 2020, an estimated $17.8M increase.
  • Sofinnova Investments's biggest Q2 2020 reduction was BioMarin Pharmaceuticals, cutting an estimated $17.6M.
  • Sofinnova Investments fully exited Alexion Pharmaceuticals in Q2 2020, selling an estimated $27.6M.
  • Sofinnova Investments's ten largest holdings make up 58% of its $1.59B portfolio in Q2 2020.
  • Sofinnova Investments opened 29 new positions and closed 17 in Q2 2020.
  • Sofinnova Investments's portfolio value rose 47% quarter-over-quarter to $1.59B.

Based on Sofinnova Investments's 13F filing for Q2 2020, filed 13 Aug 2020.